Indication

In combination with fluoropyrimidine and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with HER2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
SMC2458
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 September 2022
SMC meeting date:
02 August 2022
Patient group submission deadline:
06 June 2022